Four years after regulators began investigating alleged collusion by the banks controlling the CDS market, private antitrust litigation is finally starting to take shape.

Lions Gate, represented by Wachtell, Lipton, Rosen & Katz, claims that Icahn disingenuously criticized a proposed merger between the film studio and MGM in order to buy more holdings in the two companies at a reduced price.

Cascades Ventures Inc.--a descendant of the "original patent troll"--may have reached the end of its campaign against the self-described troll-fighter RPX Corporation and a quintet of tech companies that allegedly orchestrated an illegal boycott of Cascades's patents.

The appellate ruling comes too late to keep generic manufacturers of the colon cancer drug Eloxatin out of the market, but the Federal Circuit found that a lower court judge interpreted Sanofi's patent incorrectly when he cleared the way for its rivals.

Any court opinion that contains the words, "Crystalline 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem.-4-carboxylic acid," doesn't exactly put us in our comfort zone. Yet, upon closer inspection, it appears that the Federal Circuit's en banc decision Monday in Lupin Ltd. v. Abbott Laboratories is an important and long-awaited clarification of patent law that deserves attention. After decades of debate within the IP bar and the Federal Circuit, a divided en banc panel on Monday established the standard for evaluating so-called patent-by-process claims.

In a rare setback in Chevron and Gibson Dunn's attempts to prove that a Ecuadorian judge's $18 billion judgment was tainted by fraud, a Third Circuit panel warned U.S. judges against "disregarding or disparaging" the decisions of foreign courts.